Pre-made Ozanezumab benchmark antibody ( Whole mAb, anti-RTN4 therapeutic antibody, Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-418

Pre-Made Ozanezumab biosimilar, Whole mAb, Anti-RTN4 Antibody: Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-418-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Ozanezumab biosimilar, Whole mAb, Anti-RTN4 Antibody: Anti-ASY/NI220/250/NOGO/NSP/NSP-CL/Nbla00271/Nbla10545/RTN-X-B1-B2 therapeutic antibody
INN Name Ozanezumab
TargetRTN4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesGlaxoSmithKline
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAmyotrophic lateral sclerosis;Multiple sclerosis
Development Techna